Is Tarlatamab currently on the market globally?

Tarlatamab (Tarlatamab) is a bispecific TAmgen) >Cell-engaging antibodies, mainly targeting the DLL3 target, are suitable for the treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). The drug officially received accelerated approval from the U.S. FDA in May 2024 for adult patients with small cell lung cancer whose disease has progressed after previously receiving platinum-containing chemotherapy, marking its official launch in the United States. However, this approval is in the nature of "accelerated approval" and further clinical phase III study data is still needed to confirm its long-term efficacy and safety.

As of now, talatumumab has not yet obtained marketing authorization in other countries and regions except the United States. Although a number of Phase III clinical trials (such as the DeLLphi-304 study) have been carried out in Europe, Asia and other markets, these trials are still ongoing, so formal sales and use on a global scale have not yet been achieved. In other words, the drug is not yet widely available around the world, and patients who want to use it can only obtain it through formal medical institutions in the United States.

Talatumumab treatment is relatively expensive in the United States. According to media reports, the price of the first course of treatment of the drug is about 315USD, and the price of each subsequent course of treatment is about 3USD. The entire treatment cycle may cost more than 16USD. This poses a great challenge to the financial burden on patients and also limits its rapid promotion in other markets around the world. Most countries are still evaluating their cost-effectiveness and accessibility.

To sum up, talatumumab is currently only qualified for marketing in the U.S. market and has not yet entered the drug market in other countries and regions around the world such as China and Europe. Its global launch still needs to wait for the support of more clinical data and the approval results of regulatory agencies in various countries. If its efficacy and safety can be confirmed in the future, the drug is expected to bring new treatment options to patients with extensive-stage small cell lung cancer.

Reference materials:https://www.drugs.com/